|
Age (years)
|
< 30
|
31
|
103,146 (44,270)
|
0.6285a
|
|
30 to 50
|
65
|
107,689 (35,434)
|
|
> 50
|
112
|
102,125 (36,422)
|
|
Sex
|
F
|
87
|
99,375 (33,651)
|
0.1282b
|
|
M
|
121
|
107,353 (39,485)
|
|
Underlying disease
|
Acute leukemia and myelodysplastic syndrome
|
143
|
100,960 (31,157)
|
0.2259a
|
|
Lymphoproliferative disorder
|
46
|
111,367 (48,575)
|
|
Myeloproliferative disorder
|
12
|
116,491 (56,018)
|
|
Other
|
7
|
96,756 (22,709)
|
|
Donor type
|
HLA identical sibling
|
83
|
103,795 (41,940)
|
0.8294a
|
|
Unrelated donor
|
107
|
104,998 (33,467)
|
|
Cord blood unit
|
18
|
99,200 (37,742)
|
|
D/R match
|
HLA identical sibling
|
83
|
103,795 (41,940)
|
0.8986a
|
|
Unrelated donor 10/10 and cord blood unit 6/6
|
63
|
102,644 (32,594)
|
|
Unrelated donor 9/10 and cord blood unit 4/6 or 5/6
|
62
|
105,706 (35,598)
|
|
Stem cell source
|
Bone marrow
|
50
|
99,679 (39,183)
|
0.7950a
|
|
Peripheral blood stem cell
|
140
|
106,184 (36,604)
|
|
Cord blood unit
|
18
|
99,200 (37,742)
|
|
Conditioning regimen
|
Reduced intensity
|
92
|
108,178 (31,779)
|
0.3566a
|
|
Mini
|
61
|
101,129 (42,830)
|
|
Myeloablative
|
55
|
100,256 (39,172)
|
|
Recipient CMV serology
|
R+
|
130
|
103,494 (34,279)
|
0.7950b
|
|
R-
|
78
|
104,886 (42,030)
|
|
Number of CMV episodes
|
0
|
138
|
99,793 (39,654)
|
0.0214a
|
|
1
|
44
|
104,815 (24,271)
|
|
≥2
|
26
|
125,080 (36,290)
|
|
Acute graft-versus-host disease
|
0 and 1
|
112
|
96,278 (37,441)
|
0.0011a
|
|
2 to 4
|
96
|
113,043 (35,180)
|
|
Chronic graft-versus-host disease
|
No
|
140
|
101,858 (33,633)
|
0.2320b
|
|
Yes
|
68
|
108,458 (43,789)
|
|
Alive at the end of the mentioned period
|
No
|
80
|
109,067 (29,356)
|
0.1227b
|
|
Yes
|
128
|
100,859 (41,270)
|
|
First CMV infection
|
≤100 days
|
53
|
109,015 (30,231)
|
0.1841 b
|
|
>100 days
|
18
|
119,834 (32,142)
|
